Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph⁺ ALL

Medicine & Life Sciences

• blinatumomab 89%
• src-Family Kinases 61%
• Precursor Cell Lymphoblastic Leukemia-Lymphoma 50%
• Dasatinib 35%
• ponatinib 31%
• In Vitro Techniques 22%
• T-Lymphocytes 19%
• Interferons 17%
• Cell Proliferation 16%
• T-Cell Antigen Receptor 13%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 9%
• Imatinib Mesylate 7%
• Immunotherapy 5%
• Tissue Donors 5%
• Signal Transduction 5%
• Therapeutics 4%
• Mutation 3%

Chemical Compounds

• Ponatinib 100%
• Phosphotransferase Inhibitor 65%
• Nilotinib 30%
• Imatinib 25%
• Refractory 17%
• Mutation 14%
• Donor 11%